Kelly Blackburn
Technik-/Wissenschafts-/F&E-Leiter bei CERVOMED INC.
Vermögen: 341 713 $ am 30.04.2024
Profil
Kelly Blackburn is currently the Chief Executive Officer & Director at Bach Pharma, Inc. since 2016.
Additionally, Ms. Blackburn holds the position of Senior Vice President-Clinical Development at CervoMed, Inc. starting in 2023.
Previously, Ms. Blackburn worked as the Director-Clinical & Safety Operations at Millennium Pharmaceuticals, Inc. from 2002 to 2006.
From 2013 to 2016, Ms. Blackburn served as the Vice President-Clinical Affairs at aTyr Pharma, Inc. Ms. Blackburn also held the position of Vice President-Clinical Development Operations at Vertex, Inc. from 2006 to 2012.
Ms. Blackburn completed their undergraduate degree at the University of New Hampshire and their graduate degree at Quinnipiac College, Inc. They also obtained a graduate degree from Cambridge College Lima SRL.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CERVOMED INC.
0,17% | 29.04.2024 | 13 674 ( 0,17% ) | 341 713 $ | 30.04.2024 |
Aktive Positionen von Kelly Blackburn
| Unternehmen | Position | Beginn |
|---|---|---|
| CERVOMED INC. | Technik-/Wissenschafts-/F&E-Leiter | 16.08.2023 |
Bach Pharma, Inc.
 Bach Pharma, Inc. Pharmaceuticals: MajorHealth Technology Bach Pharma, Inc. is a private company dedicated to developing new therapeutics for the treatment of life-threatening neurodegenerative diseases. The company is based in North Andover, MA. Recently, the company has been encouraged by the effects of GVT on COVID-19 and a recent study found the effectiveness of GVT in Gulf War illness. Bach Pharma's GVT has also been featured in a Texas A&M publication. Kelly Blackburn has been the CEO of the company since 2016. | Vorstandsvorsitzender | 15.07.2016 |
Ehemalige bekannte Positionen von Kelly Blackburn
| Unternehmen | Position | Ende |
|---|---|---|
| ATYR PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2016 |
| VERTEX, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.08.2006 |
Ausbildung von Kelly Blackburn
| University of New Hampshire | Undergraduate Degree |
| Quinnipiac College, Inc. | Graduate Degree |
| Cambridge College Lima SRL | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| VERTEX, INC. | Technology Services |
| CERVOMED INC. | Commercial Services |
| Private Unternehmen | 2 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Bach Pharma, Inc.
Bach Pharma, Inc. Pharmaceuticals: MajorHealth Technology Bach Pharma, Inc. is a private company dedicated to developing new therapeutics for the treatment of life-threatening neurodegenerative diseases. The company is based in North Andover, MA. Recently, the company has been encouraged by the effects of GVT on COVID-19 and a recent study found the effectiveness of GVT in Gulf War illness. Bach Pharma's GVT has also been featured in a Texas A&M publication. Kelly Blackburn has been the CEO of the company since 2016. | Health Technology |